“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

Clovis Oncology


Clovis Oncology products


R

  • Rubraca® — rucaparib

    • Indication: a PARP inhibitor approved for:

      • Treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer in adults with deleterious or suspected deleterious BRCA mutations after ≥2 lines of chemotherapy

      • Maintenance therapy in platinum-sensitive ovarian cancer (independent of biomarker status)

    • Status: Clovis’s only marketed drug; sold in 2023 during their bankruptcy proceedings

Pipeline / Investigational

  • Lucitanib

    • A VEGFR/FGFR inhibitor under investigation for advanced solid tumors

  • 177-Lu FAP‑2286

    • A peptide-targeted radionuclide therapy (PTRT) in early clinical trials, targeting fibroblast activation protein (FAP) for oncology imaging and treatment




on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)